Health Condition 1: null- Acute on chronic liver failure with Hepato-renal Syndrome Health Condition 2: K746- Other and unspecified cirrhosis ofliver
Conditions
Interventions
Intervention1: Terlipressin: Intravenous continous infusion of terlipressin at the dose of 2 mg every 24 hours with the maximum daily cumulative dose of 12 mg/day.
In case of no response the dose of
Sponsors
Institute of liver and Biliary Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with acute on chronic liver failure presenting with hepatorenal syndrome 2. Patients consented for the study protocol by signing the informed consent
Exclusion criteria
Exclusion criteria: 1. Age less than 18 years 2. Decompensated cirrhotics 3. Patients undergoing renal replacement therapy (hemo-dialysis/renal transplantation). 4. Post liver transplantation patients. 5. History of coronary artery disease, ischaemic cardiomyopathy, ventricular arrhythmia, or peripheral vascular disease. 6. Patients with obstructive uropathy. 7. Patient who withdrew or non complaint to the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response to treatment in each intervention group.Response is defined as below: 1)Complete response was deï¬?ned as a decrease in serum creatinine to 133 lmol/L (1.5 mg/dL). 2)Partial response was deï¬?ned as a 50% serum creatinine decrease from baseline to a ï¬?nal value 133 lmol/L (1.5 mg/dL). 3) No response was deï¬?ned as a serum creatinine decrease of 50% from baseline. Timepoint: 2 days,4 days & 7 days | — |
Secondary
| Measure | Time frame |
|---|---|
| - Predictors of the treatment responseTimepoint: 28 days;- Survival at 7 days and 28 monthsTimepoint: 7 days and 28 days;Drug related Side effects/complicationsTimepoint: 28 days | — |
Countries
India
Contacts
Public ContactDr Vinod Arora
Institute of Liver and Biliary Sciences
Outcome results
None listed